About This Fund
The Penn-BioNTech Innovative Therapeutics Seed Fund, known as the PxB Fund, is a $50 million seed-stage venture capital fund launched in January 2026 as a partnership between the University of Pennsylvania, BioNTech SE, and Osage University Partners (OUP). Osage University Partners, which manages over $800 million across its university-focused fund family and partners with more than 100 institutions globally, serves as the fund's general partner and manager, with Anna Turetsky, Ph.D., appointed as General Partner for the PxB Fund.
The PxB Fund concentrates exclusively on early-stage life science companies originating from Penn's faculty and research community, targeting seed and early Series A investments in therapeutics, diagnostics, research tools, and AI-enabled drug discovery platforms. The fund's thesis builds on Penn's position as one of the world's foremost life science research institutions, with a decade of translational excellence that includes 45 FDA approvals, breakthroughs in mRNA vaccine technology and CAR T cell therapy, a Nobel Prize in Physiology or Medicine, and four Breakthrough Prizes for Life Sciences. By providing capital at the earliest commercialization stage, the PxB Fund addresses the critical valley-of-death gap between academic discovery and institutional venture funding.
The PxB Fund embodies a strategic alignment of three complementary strengths: Penn's research pipeline and translational infrastructure, BioNTech's global drug development expertise anchoring the fund's LP base, and Osage University Partners' proven track record commercializing university spinouts with over 18 IPOs and 33 acquisitions across its portfolio. For institutional investors, the fund offers curated early access to a concentrated pipeline of Penn-originated life science companies across therapeutics, diagnostics, and biomedical platforms, in a market where strong academic anchoring has historically been a significant predictor of early-stage biotech success.